동성제약

002210KOSPI

42.7 / 100

Reference Date: 2026-09-08

Financial Score9.5 / 40

News Sentiment18.2 / 25

Momentum8.0 / 20

Disclosure7.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dongseong Pharmaceutical operates 13 facilities across South Korea, with headquarters in Seoul, and is divided into three business segments: pharmaceuticals, hair dyes, and cosmetics. Key products include Jeongrohwan, Seven Eight, and Lances, with pharmaceuticals and hair dyes produced in-house at the Asan plant, while cosmetics are sold through purchased goods.

Number of Employees

307people

Average Salary

42.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

6.09Industry Average 1.200.0Point

5.1x industry avg (risky)

ROE

-76.44Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

65.78Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼629.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -32.2% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 4Neutral 1Negative 2Average Sentiment Score 72.9

Positive
정로환, 캠핑·출장 때도 마음 놓이는 '국민 지사제'
동성제약의 지사제 브랜드 정로환이 소비자 대상 브랜드 대상 수상으로 긍정적인 시장 반응을 얻었다.
Positive
미녹시딜, 머리에 뿌리고 발라 탈모 치료
동성제약의 탈모 치료제 미녹시딜이 3년 연속 브랜드 대상을 수상하며 시장 리더십을 강화했다.
Positive
보고바이오, 1999년 산삼 액체조직배양 특허 출원… 안헌식 회장 발명...
동성제약 관련 직접적 영향은 없으나, 보고바이오의 산삼 관련 특허 출원은 기업의 혁신성과 기술 경쟁력을 강화시켜 간접적으로 긍정적 영향 가능.

Detailed Momentum

52-week position5.0Point

52w mid range (57%)

Current 1,473Won52-week high 1,84652-week low 973

1-month return2.0Point

1m -2.58% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 3Negative 1

Neutral대규모기업집단현황공시[분기별공시(개별회사용)]2026-08-27
Neutral[기재정정]반기보고서 (2026.06)2026-08-18
Negative지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항2026-08-14
Neutral반기보고서 (2026.06)2026-08-14